AU2002361160B2 - Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use - Google Patents

Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use Download PDF

Info

Publication number: AU2002361160B2
Authority: AU; Australia
Prior art keywords: hcv; therapeutic; antigen; protein; seq
Prior art date: 2001-12-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

AU2002361160A

Other languages

English (en)

Other versions

AU2002361160A1 (en

Inventor

Fons Bosman

Erik Depla

Geert Maertens

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GenImmune NV

Original Assignee

GenImmune NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-18

Filing date

2002-12-18

Publication date

2008-07-03

2002-12-18 Application filed by GenImmune NV filed Critical GenImmune NV

2003-06-30 Publication of AU2002361160A1 publication Critical patent/AU2002361160A1/en

2008-04-24 Assigned to GENIMMUNE N.V. reassignment GENIMMUNE N.V. Request for Assignment Assignors: INNOGENETICS N.V.

2008-07-03 Application granted granted Critical

2008-07-03 Publication of AU2002361160B2 publication Critical patent/AU2002361160B2/en

2022-12-18 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000001225 therapeutic effect Effects 0.000 title claims description 82
241000711549 Hepacivirus C Species 0.000 title description 357
108010003533 Viral Envelope Proteins Proteins 0.000 title description 8
108090000623 proteins and genes Proteins 0.000 claims description 181
102000004169 proteins and genes Human genes 0.000 claims description 177
235000018102 proteins Nutrition 0.000 claims description 173
239000000203 mixture Substances 0.000 claims description 171
239000000427 antigen Substances 0.000 claims description 123
108091007433 antigens Proteins 0.000 claims description 122
102000036639 antigens Human genes 0.000 claims description 122
238000000034 method Methods 0.000 claims description 89
229960005486 vaccine Drugs 0.000 claims description 89
241000282414 Homo sapiens Species 0.000 claims description 62
210000002966 serum Anatomy 0.000 claims description 57
230000001684 chronic effect Effects 0.000 claims description 53
241000124008 Mammalia Species 0.000 claims description 52
230000008859 change Effects 0.000 claims description 48
206010016654 Fibrosis Diseases 0.000 claims description 46
239000002671 adjuvant Substances 0.000 claims description 41
241000700605 Viruses Species 0.000 claims description 40
230000004761 fibrosis Effects 0.000 claims description 36
238000002255 vaccination Methods 0.000 claims description 31
230000002163 immunogen Effects 0.000 claims description 29
208000019425 cirrhosis of liver Diseases 0.000 claims description 28
230000000694 effects Effects 0.000 claims description 24
208000019423 liver disease Diseases 0.000 claims description 20
102000004127 Cytokines Human genes 0.000 claims description 18
108090000695 Cytokines Proteins 0.000 claims description 18
210000001744 T-lymphocyte Anatomy 0.000 claims description 18
238000000338 in vitro Methods 0.000 claims description 18
210000004962 mammalian cell Anatomy 0.000 claims description 15
235000018417 cysteine Nutrition 0.000 claims description 14
229940037003 alum Drugs 0.000 claims description 13
230000004936 stimulating effect Effects 0.000 claims description 12
239000002245 particle Substances 0.000 claims description 10
230000028327 secretion Effects 0.000 claims description 10
210000005253 yeast cell Anatomy 0.000 claims description 9
230000001939 inductive effect Effects 0.000 claims description 6
230000007863 steatosis Effects 0.000 claims description 4
231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
150000001945 cysteines Chemical class 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 description 146
235000001014 amino acid Nutrition 0.000 description 136
210000004027 cell Anatomy 0.000 description 118
102000004196 processed proteins & peptides Human genes 0.000 description 113
230000003053 immunization Effects 0.000 description 106
229940024606 amino acid Drugs 0.000 description 105
150000001413 amino acids Chemical class 0.000 description 104
238000002649 immunization Methods 0.000 description 103
101710125507 Integrase/recombinase Proteins 0.000 description 101
238000011282 treatment Methods 0.000 description 90
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 85
101710091045 Envelope protein Proteins 0.000 description 85
101710188315 Protein X Proteins 0.000 description 85
239000013598 vector Substances 0.000 description 68
230000009257 reactivity Effects 0.000 description 62
230000004044 response Effects 0.000 description 52
230000014509 gene expression Effects 0.000 description 50
241001465754 Metazoa Species 0.000 description 41
125000003275 alpha amino acid group Chemical group 0.000 description 41
230000000638 stimulation Effects 0.000 description 39
230000013595 glycosylation Effects 0.000 description 38
238000003556 assay Methods 0.000 description 37
239000012472 biological sample Substances 0.000 description 37
238000006206 glycosylation reaction Methods 0.000 description 37
238000000746 purification Methods 0.000 description 36
208000015181 infectious disease Diseases 0.000 description 35
239000000306 component Substances 0.000 description 34
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
241000700618 Vaccinia virus Species 0.000 description 30
238000009739 binding Methods 0.000 description 30
239000013612 plasmid Substances 0.000 description 30
206010046865 Vaccinia virus infection Diseases 0.000 description 29
229920001184 polypeptide Polymers 0.000 description 29
208000007089 vaccinia Diseases 0.000 description 29
238000004587 chromatography analysis Methods 0.000 description 28
206010061218 Inflammation Diseases 0.000 description 27
238000002965 ELISA Methods 0.000 description 26
201000010099 disease Diseases 0.000 description 26
238000012544 monitoring process Methods 0.000 description 25
239000002773 nucleotide Substances 0.000 description 25
125000003729 nucleotide group Chemical group 0.000 description 25
101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 24
239000000872 buffer Substances 0.000 description 24
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
210000004185 liver Anatomy 0.000 description 24
239000000523 sample Substances 0.000 description 24
238000002560 therapeutic procedure Methods 0.000 description 24
239000012634 fragment Substances 0.000 description 23
108020004705 Codon Proteins 0.000 description 22
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 21
230000028993 immune response Effects 0.000 description 21
238000003752 polymerase chain reaction Methods 0.000 description 21
230000009467 reduction Effects 0.000 description 21
238000012360 testing method Methods 0.000 description 21
230000003612 virological effect Effects 0.000 description 21
239000000969 carrier Substances 0.000 description 20
238000001514 detection method Methods 0.000 description 20
230000004054 inflammatory process Effects 0.000 description 20
108010050904 Interferons Proteins 0.000 description 19
102000014150 Interferons Human genes 0.000 description 19
238000002523 gelfiltration Methods 0.000 description 19
229940079322 interferon Drugs 0.000 description 19
239000000243 solution Substances 0.000 description 19
229940021747 therapeutic vaccine Drugs 0.000 description 19
241000282577 Pan troglodytes Species 0.000 description 18
108010076039 Polyproteins Proteins 0.000 description 18
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
238000003018 immunoassay Methods 0.000 description 18
108010034897 lentil lectin Proteins 0.000 description 18
239000002953 phosphate buffered saline Substances 0.000 description 18
239000002299 complementary DNA Substances 0.000 description 17
239000007787 solid Substances 0.000 description 17
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 16
238000004458 analytical method Methods 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 16
238000003776 cleavage reaction Methods 0.000 description 16
150000007523 nucleic acids Chemical class 0.000 description 16
230000007017 scission Effects 0.000 description 16
240000004808 Saccharomyces cerevisiae Species 0.000 description 15
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
230000027455 binding Effects 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 15
238000003745 diagnosis Methods 0.000 description 15
238000004519 manufacturing process Methods 0.000 description 15
230000002459 sustained effect Effects 0.000 description 15
238000010504 bond cleavage reaction Methods 0.000 description 14
230000007423 decrease Effects 0.000 description 14
230000003247 decreasing effect Effects 0.000 description 14
239000003599 detergent Substances 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 14
230000036961 partial effect Effects 0.000 description 14
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
108010020567 12E7 Antigen Proteins 0.000 description 13
102000008482 12E7 Antigen Human genes 0.000 description 13
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
239000000047 product Substances 0.000 description 13
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
230000024932 T cell mediated immunity Effects 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
239000013592 cell lysate Substances 0.000 description 12
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 12
102000039446 nucleic acids Human genes 0.000 description 12
108020004707 nucleic acids Proteins 0.000 description 12
230000000405 serological effect Effects 0.000 description 12
101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 11
102000003886 Glycoproteins Human genes 0.000 description 11
108090000288 Glycoproteins Proteins 0.000 description 11
150000001720 carbohydrates Chemical class 0.000 description 11
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 11
238000012217 deletion Methods 0.000 description 11
230000037430 deletion Effects 0.000 description 11
108091033319 polynucleotide Proteins 0.000 description 11
102000040430 polynucleotide Human genes 0.000 description 11
239000002157 polynucleotide Substances 0.000 description 11
238000012216 screening Methods 0.000 description 11
239000000758 substrate Substances 0.000 description 11
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
101100228206 Caenorhabditis elegans gly-6 gene Proteins 0.000 description 10
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
229960002685 biotin Drugs 0.000 description 10
239000011616 biotin Substances 0.000 description 10
239000002981 blocking agent Substances 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
150000001875 compounds Chemical class 0.000 description 10
230000002209 hydrophobic effect Effects 0.000 description 10
230000007774 longterm Effects 0.000 description 10
239000006166 lysate Substances 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 9
241000206602 Eukaryota Species 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 9
230000000903 blocking effect Effects 0.000 description 9
230000036755 cellular response Effects 0.000 description 9
230000007882 cirrhosis Effects 0.000 description 9
238000001641 gel filtration chromatography Methods 0.000 description 9
230000008348 humoral response Effects 0.000 description 9
229940068196 placebo Drugs 0.000 description 9
239000000902 placebo Substances 0.000 description 9
238000004393 prognosis Methods 0.000 description 9
125000003396 thiol group Chemical group [H]S* 0.000 description 9
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 8
108091026890 Coding region Proteins 0.000 description 8
208000005176 Hepatitis C Diseases 0.000 description 8
108090001090 Lectins Proteins 0.000 description 8
102000004856 Lectins Human genes 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
241000282579 Pan Species 0.000 description 8
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 8
235000014633 carbohydrates Nutrition 0.000 description 8
239000003814 drug Substances 0.000 description 8
208000002672 hepatitis B Diseases 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
238000003780 insertion Methods 0.000 description 8
230000037431 insertion Effects 0.000 description 8
239000002523 lectin Substances 0.000 description 8
230000035772 mutation Effects 0.000 description 8
230000000069 prophylactic effect Effects 0.000 description 8
108010076805 snowdrop lectin Proteins 0.000 description 8
229940104230 thymidine Drugs 0.000 description 8
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 7
101100337026 Arabidopsis thaliana GLX2-2 gene Proteins 0.000 description 7
101100172745 Arabidopsis thaliana GLY3 gene Proteins 0.000 description 7
108020004414 DNA Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
241000219739 Lens Species 0.000 description 7
235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 7
108010076504 Protein Sorting Signals Proteins 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
230000002860 competitive effect Effects 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
238000012258 culturing Methods 0.000 description 7
238000011033 desalting Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
208000006454 hepatitis Diseases 0.000 description 7
235000014304 histidine Nutrition 0.000 description 7
238000011534 incubation Methods 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000012528 membrane Substances 0.000 description 7
235000021251 pulses Nutrition 0.000 description 7
230000006798 recombination Effects 0.000 description 7
238000005215 recombination Methods 0.000 description 7
238000005406 washing Methods 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
102000008070 Interferon-gamma Human genes 0.000 description 6
108010074328 Interferon-gamma Proteins 0.000 description 6
241001529936 Murinae Species 0.000 description 6
206010028851 Necrosis Diseases 0.000 description 6
230000006052 T cell proliferation Effects 0.000 description 6
239000011324 bead Substances 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003638 chemical reducing agent Substances 0.000 description 6
238000012790 confirmation Methods 0.000 description 6
238000010276 construction Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
238000012317 liver biopsy Methods 0.000 description 6
230000017074 necrotic cell death Effects 0.000 description 6
230000008569 process Effects 0.000 description 6
238000011321 prophylaxis Methods 0.000 description 6
238000001542 size-exclusion chromatography Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000001262 western blot Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
239000000020 Nitrocellulose Substances 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
108010090804 Streptavidin Proteins 0.000 description 5
230000005867 T cell response Effects 0.000 description 5
238000001261 affinity purification Methods 0.000 description 5
230000000692 anti-sense effect Effects 0.000 description 5
235000020958 biotin Nutrition 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
239000000356 contaminant Substances 0.000 description 5
230000016396 cytokine production Effects 0.000 description 5
230000002950 deficient Effects 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
238000009472 formulation Methods 0.000 description 5
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 5
206010073071 hepatocellular carcinoma Diseases 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
229960003130 interferon gamma Drugs 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
230000002934 lysing effect Effects 0.000 description 5
239000012139 lysis buffer Substances 0.000 description 5
239000003550 marker Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
238000002703 mutagenesis Methods 0.000 description 5
231100000350 mutagenesis Toxicity 0.000 description 5
229920001220 nitrocellulos Polymers 0.000 description 5
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000013207 serial dilution Methods 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
210000003501 vero cell Anatomy 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
108090001008 Avidin Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010074860 Factor Xa Proteins 0.000 description 4
102000007474 Multiprotein Complexes Human genes 0.000 description 4
GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 4
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 4
208000037581 Persistent Infection Diseases 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
239000013504 Triton X-100 Substances 0.000 description 4
229920004890 Triton X-100 Polymers 0.000 description 4
230000003321 amplification Effects 0.000 description 4
230000005875 antibody response Effects 0.000 description 4
238000002820 assay format Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000004737 colorimetric analysis Methods 0.000 description 4
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
230000008034 disappearance Effects 0.000 description 4
238000011049 filling Methods 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
231100000283 hepatitis Toxicity 0.000 description 4
230000028996 humoral immune response Effects 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
230000004904 long-term response Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000012546 transfer Methods 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
241000701447 unidentified baculovirus Species 0.000 description 4
101710186708 Agglutinin Proteins 0.000 description 3
108010039627 Aprotinin Proteins 0.000 description 3
208000002109 Argyria Diseases 0.000 description 3
101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 3
101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 3
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 3
206010008909 Chronic Hepatitis Diseases 0.000 description 3
206010057573 Chronic hepatic failure Diseases 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
208000010334 End Stage Liver Disease Diseases 0.000 description 3
206010073069 Hepatic cancer Diseases 0.000 description 3
101710146024 Horcolin Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
101710189395 Lectin Proteins 0.000 description 3
206010067125 Liver injury Diseases 0.000 description 3
101710179758 Mannose-specific lectin Proteins 0.000 description 3
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 3
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
102000006601 Thymidine Kinase Human genes 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
206010058874 Viraemia Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000000910 agglutinin Substances 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
229960004405 aprotinin Drugs 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
208000011444 chronic liver failure Diseases 0.000 description 3
238000003759 clinical diagnosis Methods 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
238000000326 densiometry Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000010828 elution Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
231100000234 hepatic damage Toxicity 0.000 description 3
208000010710 hepatitis C virus infection Diseases 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
201000002250 liver carcinoma Diseases 0.000 description 3
230000008818 liver damage Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
229940126619 mouse monoclonal antibody Drugs 0.000 description 3
230000003041 necroinflammatory effect Effects 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
238000010606 normalization Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000002516 postimmunization Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012552 review Methods 0.000 description 3
229960000329 ribavirin Drugs 0.000 description 3
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
QPYAUURPGVXHFK-UHFFFAOYSA-N 1-[4-(dimethylamino)-3,5-dinitrophenyl]pyrrole-2,5-dione Chemical compound C1=C([N+]([O-])=O)C(N(C)C)=C([N+]([O-])=O)C=C1N1C(=O)C=CC1=O QPYAUURPGVXHFK-UHFFFAOYSA-N 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
ROUFCTKIILEETD-UHFFFAOYSA-N 5-nitro-2-[(5-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound N1=CC([N+](=O)[O-])=CC=C1SSC1=CC=C([N+]([O-])=O)C=N1 ROUFCTKIILEETD-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
102100033814 Alanine aminotransferase 2 Human genes 0.000 description 2
101710096000 Alanine aminotransferase 2 Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
239000006145 Eagle's minimal essential medium Substances 0.000 description 2
101710204837 Envelope small membrane protein Proteins 0.000 description 2
102000001690 Factor VIII Human genes 0.000 description 2
108010054218 Factor VIII Proteins 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
206010060708 Induration Diseases 0.000 description 2
206010022004 Influenza like illness Diseases 0.000 description 2
101710128560 Initiator protein NS1 Proteins 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
206010024769 Local reaction Diseases 0.000 description 2
101710145006 Lysis protein Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
101710144127 Non-structural protein 1 Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
241000235648 Pichia Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
241000288906 Primates Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000235346 Schizosaccharomyces Species 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
108700010756 Viral Polyproteins Proteins 0.000 description 2
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000005903 acid hydrolysis reaction Methods 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
230000001745 anti-biotin effect Effects 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000022811 deglycosylation Effects 0.000 description 2
239000003398 denaturant Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
210000002288 golgi apparatus Anatomy 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000008102 immune modulation Effects 0.000 description 2
230000037451 immune surveillance Effects 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
238000013507 mapping Methods 0.000 description 2
230000015654 memory Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000000178 monomer Substances 0.000 description 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
229940078490 n,n-dimethylglycine Drugs 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
238000007857 nested PCR Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 2
230000037361 pathway Effects 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
229910000160 potassium phosphate Inorganic materials 0.000 description 2
235000011009 potassium phosphates Nutrition 0.000 description 2
238000009021 pre-vaccination Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
235000004252 protein component Nutrition 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
239000006152 selective media Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
208000002491 severe combined immunodeficiency Diseases 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
239000002356 single layer Substances 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
241000894007 species Species 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
239000013638 trimer Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QSZRHMZKUUXBNB-LOLRQIBTSA-N (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid 5-[(3-carboxy-4-nitrophenyl)disulfanyl]-2-nitrobenzoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 QSZRHMZKUUXBNB-LOLRQIBTSA-N 0.000 description 1
DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 description 1
KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
BKBPZDOOPJRQCL-UHFFFAOYSA-N 6-chloro-2-n,4-n-diethyl-1,3,5-triazine-2,4-diamine;6-methylsulfanyl-2-n,4-n-di(propan-2-yl)-1,3,5-triazine-2,4-diamine Chemical compound CCNC1=NC(Cl)=NC(NCC)=N1.CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 BKBPZDOOPJRQCL-UHFFFAOYSA-N 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
244000003363 Allium ursinum Species 0.000 description 1
235000005336 Allium ursinum Nutrition 0.000 description 1
KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
241000486679 Antitype Species 0.000 description 1
101100337028 Arabidopsis thaliana GLX2-1 gene Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000700663 Avipoxvirus Species 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241001118702 Border disease virus Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
101100268665 Caenorhabditis elegans acc-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108010039939 Cell Wall Skeleton Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
208000006154 Chronic hepatitis C Diseases 0.000 description 1
241000710777 Classical swine fever virus Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
102100031673 Corneodesmosin Human genes 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
206010072268 Drug-induced liver injury Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
241001288713 Escherichia coli MC1061 Species 0.000 description 1
208000004930 Fatty Liver Diseases 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
241000714188 Friend murine leukemia virus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
101150108526 GLY1 gene Proteins 0.000 description 1
208000027472 Galactosemias Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000288105 Grus Species 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000711557 Hepacivirus Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
206010019791 Hepatitis post transfusion Diseases 0.000 description 1
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
101150081923 IL4 gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
241000194036 Lactococcus Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
241001532689 Narcissus pseudonarcissus Species 0.000 description 1
101800001020 Non-structural protein 4A Proteins 0.000 description 1
101800001019 Non-structural protein 4B Proteins 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108010036939 Occlusion Body Matrix Proteins Proteins 0.000 description 1
241000320412 Ogataea angusta Species 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
240000004713 Pisum sativum Species 0.000 description 1
235000010582 Pisum sativum Nutrition 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108010073443 Ribi adjuvant Proteins 0.000 description 1
108010017507 Ricinus communis agglutinin-1 Proteins 0.000 description 1
NOKPBJYHPHHWAN-REOHCLBHSA-N S-sulfo-L-cysteine Chemical compound OC(=O)[C@@H](N)CSS(O)(=O)=O NOKPBJYHPHHWAN-REOHCLBHSA-N 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
241001123227 Saccharomyces pastorianus Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
101100445369 Solanum lycopersicum EOT1 gene Proteins 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
241000282890 Sus Species 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
241001664469 Tibicina haematodes Species 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
241000700646 Vaccinia virus WR Species 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
206010051511 Viral diarrhoea Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000018839 Wilson disease Diseases 0.000 description 1
241000235017 Zygosaccharomyces Species 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
231100000354 acute hepatitis Toxicity 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000012491 analyte Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Chemical group CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000009875 biological transport Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
239000012503 blood component Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
210000004520 cell wall skeleton Anatomy 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000009920 chelation Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
235000021310 complex sugar Nutrition 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000006334 disulfide bridging Effects 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
-1 for example Chemical class 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000004730 hepatocarcinogenesis Effects 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical class 0.000 description 1
150000002411 histidines Chemical class 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229940100602 interleukin-5 Drugs 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000006372 lipid accumulation Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
229960003151 mercaptamine Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
150000002482 oligosaccharides Polymers 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
108040002068 peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity proteins Proteins 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
238000011946 reduction process Methods 0.000 description 1
238000002407 reforming Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
125000005629 sialic acid group Chemical group 0.000 description 1
238000007873 sieving Methods 0.000 description 1
230000037432 silent mutation Effects 0.000 description 1
238000013424 sirius red staining Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
XUPZAARQDNSRJB-SJDTYFKWSA-N trans-dothiepin hydrochloride Chemical compound [Cl-].C1SC2=CC=CC=C2C(=C/CC[NH+](C)C)/C2=CC=CC=C21 XUPZAARQDNSRJB-SJDTYFKWSA-N 0.000 description 1
102000014898 transaminase activity proteins Human genes 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000008957 viral persistence Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2002361160A 2001-12-18 2002-12-18 Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use Expired - Fee Related AU2002361160B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US2051001A	2001-12-18	2001-12-18
US10/020,510		2001-12-18
US41835802P	2002-10-16	2002-10-16
US60/418,358		2002-10-16
PCT/EP2002/014480 WO2003051912A2 (fr)	2001-12-18	2002-12-18	Proteines purifiees du virus de l'hepatite c utilisables en diagnostic et therapie

Publications (2)

Publication Number	Publication Date
AU2002361160A1 AU2002361160A1 (en)	2003-06-30
AU2002361160B2 true AU2002361160B2 (en)	2008-07-03

Family

ID=26693530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002361160A Expired - Fee Related AU2002361160B2 (en)	2001-12-18	2002-12-18	Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use

Country Status (12)

Country	Link
EP (1)	EP1461080A2 (fr)
JP (1)	JP2005516939A (fr)
KR (1)	KR20040076869A (fr)
CN (1)	CN1622828A (fr)
AU (1)	AU2002361160B2 (fr)
BR (1)	BR0215081A (fr)
CA (1)	CA2468690A1 (fr)
IL (1)	IL162236A0 (fr)
MX (1)	MXPA04005891A (fr)
NZ (1)	NZ533396A (fr)
RU (1)	RU2319505C2 (fr)
WO (1)	WO2003051912A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7108855B2 (en)	1998-06-24	2006-09-19	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7101561B2 (en)	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1414942A2 (fr)	2001-04-24	2004-05-06	Innogenetics N.V.	Expression, dans la levure, de proteines de l'enveloppe du virus de l'hepatite c (vhc) a nucleo-glycosylation
FR2859221B1 (fr) *	2003-08-28	2005-10-14	Centre Nat Rech Scient	Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations
EP1574517A1 (fr)	2004-03-09	2005-09-14	Innogenetics N.V.	HCV E1 contenant les ponts disulfure spécifiques
EP1809773B1 (fr) *	2004-10-18	2014-07-16	Globeimmune, Inc.	Moyens therapeutiques a base de levure contre l'infection par hepatite c chronique
CN100365124C (zh) *	2005-10-27	2008-01-30	云南大学	一段丙型肝炎病毒特异性cDNA序列的应用
WO2009030872A1 (fr) *	2007-09-07	2009-03-12	Mats Axel Atterdag Persson	Matériaux et procédés pour le traitement de l'hépatite c
DK2285408T3 (en)	2008-06-05	2019-02-04	Ablynx Nv	AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
RU2016103067A (ru)	2009-06-05	2018-11-20	Аблинкс Нв	Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
EP2507262A1 (fr)	2009-11-30	2012-10-10	Ablynx N.V.	Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
SG195383A1 (en)	2011-06-14	2013-12-30	Globeimmune Inc	Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
RU2570553C2 (ru) *	2013-11-20	2015-12-10	Федеральное бюджетное учреждение "Всероссийский научно-исследовательский институт лесоводства и механизации лесного хозяйства (ФБУ ВНИИЛМ)	Способ очистки вирусных полиэдров
CN104327170A (zh) *	2014-05-16	2015-02-04	中国疾病预防控制中心病毒病预防控制所	丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CA2961568A1 (fr)	2014-09-17	2016-03-24	The University Of Iowa Research Foundation	Segments d'arn viral utilises en tant qu'agents immunomodulateurs et composants de vaccin
AU2017334263B2 (en) *	2016-09-29	2024-11-28	Macfarlane Burnet Institute For Medical Research And Public Health Limited	Assembled glycoproteins
WO2020117760A1 (fr) *	2018-12-03	2020-06-11	Duke University	Procédé de purification de nanoparticules et de protéines recombinantes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6555114B1 (en) *	1993-11-04	2003-04-29	Innogenetics N.V.	Immunodominant human T-cell epitopes of hepatitis C virus
JP2002518037A (ja) *	1998-06-24	2002-06-25	イノジェネティックス・ナムローゼ・フェンノートシャップ	Ｈｃｖエンベロープ蛋白の粒子：ワクチン接種への使用

2002
- 2002-12-18 IL IL16223602A patent/IL162236A0/xx unknown
- 2002-12-18 RU RU2004116914/15A patent/RU2319505C2/ru not_active IP Right Cessation
- 2002-12-18 EP EP02796675A patent/EP1461080A2/fr not_active Withdrawn
- 2002-12-18 CN CNA028282027A patent/CN1622828A/zh active Pending
- 2002-12-18 WO PCT/EP2002/014480 patent/WO2003051912A2/fr active IP Right Grant
- 2002-12-18 NZ NZ533396A patent/NZ533396A/en unknown
- 2002-12-18 KR KR10-2004-7009720A patent/KR20040076869A/ko not_active Ceased
- 2002-12-18 AU AU2002361160A patent/AU2002361160B2/en not_active Expired - Fee Related
- 2002-12-18 BR BR0215081-6A patent/BR0215081A/pt not_active IP Right Cessation
- 2002-12-18 CA CA002468690A patent/CA2468690A1/fr not_active Abandoned
- 2002-12-18 JP JP2003552792A patent/JP2005516939A/ja active Pending
2004
- 2004-06-16 MX MXPA04005891A patent/MXPA04005891A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2002361160A1 (en)	2003-06-30
CA2468690A1 (fr)	2003-06-26
KR20040076869A (ko)	2004-09-03
EP1461080A2 (fr)	2004-09-29
WO2003051912A3 (fr)	2004-03-04
RU2319505C2 (ru)	2008-03-20
MXPA04005891A (es)	2004-09-13
JP2005516939A (ja)	2005-06-09
WO2003051912A9 (fr)	2004-07-15
WO2003051912A2 (fr)	2003-06-26
NZ533396A (en)	2005-04-29
RU2004116914A (ru)	2005-04-20
IL162236A0 (en)	2005-11-20
CN1622828A (zh)	2005-06-01
BR0215081A (pt)	2004-10-19

Legal Events

Date

Code

Title

Description

2008-04-24

PC1

Assignment before grant (sect. 113)

Owner name: GENIMMUNE N.V.

Free format text: FORMER APPLICANT(S): INNOGENETICS N.V.

2008-11-06

MK25

Application lapsed reg. 22.2i(2) - failure to pay acceptance fee

Publication	Publication Date	Title
US6890737B1 (en)	2005-05-10	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002361160B2 (en)	2008-07-03	Purified Hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7101561B2 (en)	2006-09-05	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20040126395A1 (en)	2004-07-01	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002238502B2 (en)	2007-09-06	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7108855B2 (en)	2006-09-19	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030095980A1 (en)	2003-05-22	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU757962B2 (en)	2003-03-13	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
ZA200405218B (en)	2005-07-12	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use.
AU708174B2 (en)	1999-07-29	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
NZ521299A (en)	2005-08-26	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
ZA200207272B (en)	2004-02-13	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use.
JP2004525885A (ja)	2004-08-26	診断用および治療用の精製ｃ型肝炎ウイルスエンベロープタンパク質